CXCL8 and myelofibrosis: Thus targeting the IL-8/CXCR1/CXCR2 axis might be another promising avenue for clinical exploration in AML, as well as other myeloid malignancies in which high IL-8 expression has been pathologically implicated, including MDS (Shi et al., 2019), CMML (Niyongere et al., 2018), and myelofibrosis (Tefferi et al., 2011).